VISEN Pharmaceuticals (2561) Stock Statistics & Valuation Metrics

VISEN Pharmaceuticals has a market cap or net worth of HK$4.33B. The enterprise value is HK$3.88B.

VISEN Pharmaceuticals has 113,926,865 shares outstanding. The number of shares has decreased by -2.65% in one year.

VISEN Pharmaceuticals’s return on equity (ROE) is -0.76 and return on invested capital (ROIC) is -71.49%.

The current PE Ratio of VISEN Pharmaceuticals is ―. VISEN Pharmaceuticals’s PEG ratio is 1.23.

In the last 12 months, VISEN Pharmaceuticals had revenue of 2.78M and earned -182.24M in profits. Earnings per share was -1.95.

In the last 12 months, operating cash flow was -147.14M and capital expenditures 0.00, giving a free cash flow of -147.14M billion.

VISEN Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

VISEN Pharmaceuticals upcoming earnings date is Aug 27, 2025, Before Open (Confirmed).

VISEN Pharmaceuticals as a current ratio of 4.26, with Debt / Equity ratio of 0.14%

In the past 12 months, VISEN Pharmaceuticals has paid 0.00 in taxes.

VISEN Pharmaceuticals EV to EBITDA ratio is -32.93, with an EV/FCF ratio of -41.49.

VISEN Pharmaceuticals has HK$805.91M in cash and marketable securities with HK$1.20M in debt, giving a net cash position of HK$804.71M billion.

Gross margin is 100.00%, with operating margin of -6272.16%, and net profit margin of -6562.55%.

The average price target for VISEN Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is ―